Loading clinical trials...
Loading clinical trials...
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT01399385 · Healthy, Obesity, and more
NCT00353782 · Hypercholesterolemia, Atherosclerosis
NCT01143454 · Metabolic Disease, Obesity, and more
NCT07241390 · Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
NCT05316311 · Intracranial Atherosclerosis
Novartis Investigative Site
Athens, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions